Alembic Pharmaceuticals announces USFDA final approval for Nelarabine injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial) Read more
Successful completion of USFDA inspection at Alembic Pharma Oral Solid Formulation Facility (F-I) at Panelav Read more
Eisai and Biogen’s Leqembi launch in China marks turning point in Alzheimer’s treatment, says GlobalData Read more